

02-08-2023

Home

lournal

Articles 🕶

Medi News 🕶

Features >

Interviews •


Opinions •

Events

C

Asprius Lifesciences Develops Drug for Diabetic Neuropathy and Has Applied for Patent

Diabetic Neuropathy



Asprius Lifesciences, a pharmaceutical company based in Gujarat, has made a significant announcement regarding the development of a treatment for Diabetic Neuropathy, a condition that leads to nerve damage in peripheral areas of the body. The company has already applied for a patent for its Fixed-Dose Combination (FDC) drug, which shows great promise in addressing peripheral neuropathy, a prevalent condition affecting more than 2 percent of the global population.

Chairman and Managing Director of Asprius Lifesciences, Vishal Zinzuwadia, emphasized the company's commitment to fostering innovation and creating groundbreaking pharmaceutical products. Their primary objective is to empower the medical community and improve patient care, particularly when conventional therapies fall short. By actively focusing on medical conditions that increase the risk of neuropathy development and introducing neuroprotective medications, Asprius aims to support early neuronal regeneration and minimize the impact of this condition.

Highlighting the urgency of addressing Diabetic Neuropathy in the country, the company's Medical Director, Dr. Sanjay Agrawal, pointed out that India has a high prevalence of diabetes, with an estimated 77 million adults currently living with the disease, projected to rise to 101.2 million by 2030. Type 2 diabetes, which is often linked to lifestyle factors such as poor diet, sedentary lifestyle, and obesity, accounts for around 90-95% of all diabetes cases in India. Therefore, it is crucial to tackle this widespread condition, especially considering that Diabetic Neuropathy can cause damage to specific parts of the nervous system.

Dr. Agrawal, the inventor of this new formulation, added that Diabetic Neuropathy is highly common, and until now, no specific line of treatment has been available for it. The development of this drug by Asprius Lifesciences represents a significant step forward in addressing this medical challenge.